Previous investigators have reported the characteristics and clinical impact of CDKN2A/B deletions in pediatric ALL, and the prognostic importance of CDKN2A/B deletions in pediatric ALL is still controversial (2, 4, 5, 10, 19). Here, CDKN2A is linked to acute lymphoblastic leukemia.